In this presentation, Anand A. Patel, MD, reviewed the contemporary standard-of-care treatment roadmap for AML in 2025, covering key phases like induction chemotherapy (eg, the “7+3” regimen), consolidation with options such as CPX-351, and the role of stem cell transplantation. He also emphasized the importance of molecular profiling and the integration of targeted therapies, such as FLT3 inhibitors, in both initial and relapse settings.
Naval G. Daver, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, highlights findings from the randomized phase…
Eunice Wang, MD, chief of the Leukemia Service at the Roswell Park Comprehensive Cancer Center, discusses the outlook of acute myeloid leukemia (AML) treatment in the wake of…
In a presentation at the 2024 International Pathology Day virtual conference, Dr Justin Loke, CRUK/AACR Transatlantic Fellow, University of Birmingham, UK and Dana-Farber Cancer Institute, USA, explains how…
Alice S. Mims, MD, of The Ohio State University’s James Comprehensive Cancer Center, provided an overview of current AML treatment options, such as FLT3 and IDH inhibitors, while…
Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma, discusses acute myeloid leukemia (AML) in the context of the COVID-19 pandemic. The prevalence of healthcare disparities…
In this video, Naval G. Daver, MD, a professor and director of the Leukemia Research Alliance Program, MD Anderson Cancer Center, Houston, Texas, and Uma Borate, MBBS, Acute…
The American Society of Hematology (ASH) has released 2020 guidelines for treating newly diagnosed acute myeloid leukemia (AML) in older adults. Specifically, the guidelines help patients and doctors…
In this expert interview, Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses donor selection for allogeneic stem cell transplantation in secondary acute myeloid leukemia (AML) patients…
Rebecca L. Olin, MD, MSCE, associate professor in the Department of Medicine at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses changes in…
